Characteristics and co-morbidities associated with hospital discharges for opioid and methamphetamine co-use, United States 2016–2019
Introduction: The US overdose crisis is increasingly characterized by opioid and methamphetamine co-use. Hospitalization is an important opportunity to engage patients in substance use treatment. Understanding characteristics of co-use-related hospital stays can inform the development of services to...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2024-03-01
|
| Series: | Drug and Alcohol Dependence Reports |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2772724624000039 |
| _version_ | 1827311770367164416 |
|---|---|
| author | Riley D. Shearer Nathan D. Shippee Beth A. Virnig Timothy J. Beebe Tyler N.A. Winkelman |
| author_facet | Riley D. Shearer Nathan D. Shippee Beth A. Virnig Timothy J. Beebe Tyler N.A. Winkelman |
| author_sort | Riley D. Shearer |
| collection | DOAJ |
| description | Introduction: The US overdose crisis is increasingly characterized by opioid and methamphetamine co-use. Hospitalization is an important opportunity to engage patients in substance use treatment. Understanding characteristics of co-use-related hospital stays can inform the development of services to better support this growing patient population. Methods: We used 2016–2019 National Inpatient Sample data to conduct a cross sectional analysis of hospitalizations involving use of opioids, methamphetamine, or both. We used bivariate analysis to compare patient demographics. We then used multinomial logistic regressions to compare the proportion of hospital stays which indicated co-morbid diagnosis. To account for correlated data, we used generalized linear models to compare outcomes in hospital mortality, patient-directed discharge, and length of stay. Results: Co-use-related stays had a higher proportion of co-morbid mental health (60.7%; 95% CI: 59.9–61.4%) and infectious diseases (41.5%; 95% CI: 40.8–42.2%), than opioid- or methamphetamine-related stays. Co-use-related stays increased between 2016 and 2019 and were associated with a higher proportion of patient directed discharge (10.7%; 95% CI: 10.4–11.0%) and longer length of stay (6.3 days; 95% CI: 6.2–6.4 days) compared to opioid (8.1%; 95% CI: 7.9–8.3% and 5.8 days; 95% CI: 5.8–5.9 days) and methamphetamine-related stays (6.5%; 95% CI: 6.3–6.6% and 5.5 days; 95% CI: 5.4–5.5 days). Conclusion: Patients discharged with co-use differ from patients with opioid or methamphetamine use alone, representing a range of challenges and opportunities. In addition to offering treatment for both substance use disorders, hospital-based services that address co-occurring conditions may better support patients with co-use through targeted and tailored approaches. |
| first_indexed | 2024-03-08T04:07:06Z |
| format | Article |
| id | doaj.art-edf0ce47ae1f4c08b5b2f0afc965fc41 |
| institution | Directory Open Access Journal |
| issn | 2772-7246 |
| language | English |
| last_indexed | 2024-04-24T20:25:23Z |
| publishDate | 2024-03-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Drug and Alcohol Dependence Reports |
| spelling | doaj.art-edf0ce47ae1f4c08b5b2f0afc965fc412024-03-22T05:41:18ZengElsevierDrug and Alcohol Dependence Reports2772-72462024-03-0110100219Characteristics and co-morbidities associated with hospital discharges for opioid and methamphetamine co-use, United States 2016–2019Riley D. Shearer0Nathan D. Shippee1Beth A. Virnig2Timothy J. Beebe3Tyler N.A. Winkelman4University of Minnesota School of Public Health, 420 Delaware St SE, Mayo Building B681, Minneapolis, MN, 55455 USA; Health, Homelessness, and Criminal Justice Lab, Hennepin Healthcare Research Institute, 701 Park Ave., Suite PP7.700, Minneapolis, MN, 55415, USA; Corresponding author at: University of Minnesota Medical School, 420 Delaware St. Minneapolis, MN 55455.University of Minnesota School of Public Health, 420 Delaware St SE, Mayo Building B681, Minneapolis, MN, 55455 USACollege of Public Health and Health Professions, University of Florida, 1225 Center Drive, Gainsville, FL, 32611, USAUniversity of Minnesota School of Public Health, 420 Delaware St SE, Mayo Building B681, Minneapolis, MN, 55455 USAHealth, Homelessness, and Criminal Justice Lab, Hennepin Healthcare Research Institute, 701 Park Ave., Suite PP7.700, Minneapolis, MN, 55415, USA; Division of General Internal Medicine, Department of Medicine, Hennepin Healthcare, 716 S 7th St, Minneapolis, MN, 55415, USAIntroduction: The US overdose crisis is increasingly characterized by opioid and methamphetamine co-use. Hospitalization is an important opportunity to engage patients in substance use treatment. Understanding characteristics of co-use-related hospital stays can inform the development of services to better support this growing patient population. Methods: We used 2016–2019 National Inpatient Sample data to conduct a cross sectional analysis of hospitalizations involving use of opioids, methamphetamine, or both. We used bivariate analysis to compare patient demographics. We then used multinomial logistic regressions to compare the proportion of hospital stays which indicated co-morbid diagnosis. To account for correlated data, we used generalized linear models to compare outcomes in hospital mortality, patient-directed discharge, and length of stay. Results: Co-use-related stays had a higher proportion of co-morbid mental health (60.7%; 95% CI: 59.9–61.4%) and infectious diseases (41.5%; 95% CI: 40.8–42.2%), than opioid- or methamphetamine-related stays. Co-use-related stays increased between 2016 and 2019 and were associated with a higher proportion of patient directed discharge (10.7%; 95% CI: 10.4–11.0%) and longer length of stay (6.3 days; 95% CI: 6.2–6.4 days) compared to opioid (8.1%; 95% CI: 7.9–8.3% and 5.8 days; 95% CI: 5.8–5.9 days) and methamphetamine-related stays (6.5%; 95% CI: 6.3–6.6% and 5.5 days; 95% CI: 5.4–5.5 days). Conclusion: Patients discharged with co-use differ from patients with opioid or methamphetamine use alone, representing a range of challenges and opportunities. In addition to offering treatment for both substance use disorders, hospital-based services that address co-occurring conditions may better support patients with co-use through targeted and tailored approaches.http://www.sciencedirect.com/science/article/pii/S2772724624000039OpioidMethamphetaminePolysubstance useHospitalAddiction medicine servicesSubstance use treatment |
| spellingShingle | Riley D. Shearer Nathan D. Shippee Beth A. Virnig Timothy J. Beebe Tyler N.A. Winkelman Characteristics and co-morbidities associated with hospital discharges for opioid and methamphetamine co-use, United States 2016–2019 Drug and Alcohol Dependence Reports Opioid Methamphetamine Polysubstance use Hospital Addiction medicine services Substance use treatment |
| title | Characteristics and co-morbidities associated with hospital discharges for opioid and methamphetamine co-use, United States 2016–2019 |
| title_full | Characteristics and co-morbidities associated with hospital discharges for opioid and methamphetamine co-use, United States 2016–2019 |
| title_fullStr | Characteristics and co-morbidities associated with hospital discharges for opioid and methamphetamine co-use, United States 2016–2019 |
| title_full_unstemmed | Characteristics and co-morbidities associated with hospital discharges for opioid and methamphetamine co-use, United States 2016–2019 |
| title_short | Characteristics and co-morbidities associated with hospital discharges for opioid and methamphetamine co-use, United States 2016–2019 |
| title_sort | characteristics and co morbidities associated with hospital discharges for opioid and methamphetamine co use united states 2016 2019 |
| topic | Opioid Methamphetamine Polysubstance use Hospital Addiction medicine services Substance use treatment |
| url | http://www.sciencedirect.com/science/article/pii/S2772724624000039 |
| work_keys_str_mv | AT rileydshearer characteristicsandcomorbiditiesassociatedwithhospitaldischargesforopioidandmethamphetaminecouseunitedstates20162019 AT nathandshippee characteristicsandcomorbiditiesassociatedwithhospitaldischargesforopioidandmethamphetaminecouseunitedstates20162019 AT bethavirnig characteristicsandcomorbiditiesassociatedwithhospitaldischargesforopioidandmethamphetaminecouseunitedstates20162019 AT timothyjbeebe characteristicsandcomorbiditiesassociatedwithhospitaldischargesforopioidandmethamphetaminecouseunitedstates20162019 AT tylernawinkelman characteristicsandcomorbiditiesassociatedwithhospitaldischargesforopioidandmethamphetaminecouseunitedstates20162019 |